Zineb Boukhal, Manar Fartmissi*, Rihab El Amiri, Fatima Zahra El Rhaoussi, Mohamed Tahiri, Fouad Haddad, Wafaa Hliwa, Ahmed Bellabah and Wafaa Badre

Department of Gastroenterology and Hepatology, Ibn Rochd University Hospital Center, Casablanca, Morocco

*Corresponding Author: Manar Fartmissi, Department of Gastroenterology and Hepatology, Ibn Rochd University Hospital Center, Casablanca, Morocco.

Received: February 12, 2026; Published: May 04, 2026

Abstract

Background: Drug-induced acute pancreatitis (DIAP) is an uncommon etiology of acute pancreatitis and remains a diagnosis of exclusion. Tumor necrosis factor-alpha (TNF-α) inhibitors are widely used in inflammatory bowel disease, but acute pancreatitis has only rarely been reported with these agents.

Case Presentation: We describe a 30-year-old man with pancolonic ulcerative colitis treated with adalimumab who developed acute pancreatitis during maintenance therapy. The patient presented with intermittent epigastric pain associated with a marked elevation of serum lipase. Cross-sectional imaging and magnetic resonance cholangiopancreatography showed no pancreatic or biliary abnormalities. A comprehensive etiological workup excluded gallstone disease, alcohol use, metabolic disorders, and autoimmune pancreatitis. Clinical and biochemical improvement occurred after discontinuation of adalimumab.
Conclusion: This case supports adalimumab as a rare but possible cause of acute pancreatitis. Awareness of this adverse event and a structured causality assessment are essential to guide management and prevent recurrence.

Keywords: Ulcerative Colitis; Adalimumab; Anti-TNF; Drug-induced pancreatitis

References

1. Nitsche CJ., et al. “Drug induced pancreatitis”. Best Practice and Research Clinical Gastroenterology2 (2010): 143‑155.
2. Badalov N., et al. “Drug-Induced Acute Pancreatitis: An Evidence-Based Review”. Clinical Gastroenterology and Hepatology6 (2007): 648-661.e3.
3. Bhalla R., et al. “Tumor Necrosis Factor α (TNFα) Inhibitor Class Induced Acute Pancreatitis: 1049”. Official Journal of the American College of Gastroenterology | ACG 109 (2014): S312.
4. Werlang ME., et al. “Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis”. ACG Case Reports Journal1 (2017): e103.
5. Balani AR and Grendell JH. “Drug-Induced Pancreatitis: Incidence, Management and Prevention”. Drug Safety10 (2008): 823‑837.
6. Hung WY. “Contemporary review of drug-induced pancreatitis: A different perspective”. WJGP4 (2014): 405.
7. Lancashire RJ., et al. “Discrepancies between population‐based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis”. Aliment Pharmacology Therapy7 (2003): 887‑893.
8. Jones MR., et al. “Drug-Induced Acute Pancreatitis: A Review”. 15.1 (2015).
9. Bezzio C., et al. “Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations”. Therapy Advances in Gastroenterology 15 (2022): 17562848221115312.
10. Tsen A., et al. “Autoimmune Pancreatitis and Inflammatory Bowel Disease: An Updated Review”. Journal of Clinical Gastroenterology3 (2017): 208‑214.
11. El Ouardi W and Benazzouz M. “Acute Pancreatitis: An Unusual Side Effect of Adalimumab in Crohn’s Disease Patient”. Clinical Medicine Insights: Case Reports 18 (2025): 11795476251315000.

Citation

Citation: Manar Fartmissi., et al. “Adalimumab-Associated Acute Pancreatitis in a Patient with Ulcerative Colitis: A Case Report". Acta Scientific Gastrointestinal Disorders 9.2 (2026): 27-30.

Copyright

Copyright: © 2026 Manar Fartmissi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.